As you know, EPO is currently the focus and at the forefront of Xenetic's efforts to monetise their various drug candidates. As I wrote in an earlier post, the Company has yet to have a setback (apart from inevitable delays, the bane of the industry) in its various trials and EPO is no exception. Rather the contrary - in terms of efficacy and performance against its peers, EPO looks like it might be the go-to drug of the future, if they can keep bringing in the results.
If and when EPO is licensed out and royalties begin to be earned, this will open up the path for other Xenetic candidates to progress through their various phases - most notably OncoHist, a very promising orphan cancer candidate being developed in conjunction with Dana-Farber, already into Phase II.